Genitourinary Cancers Symposium Annual Meeting Coverage
Treatment-naïve patients with advanced clear-cell renal cell carcinoma had significantly longer progression-free survival when treated with pazopanib instead of temsirolimus.
Added to hormone therapy, docetaxel offers a cost effective way to prolong hormone-sensitive disease and improve quality of life years, especially among men with non-metastatic disease, study finds.
Patients with bladder adenocarcinomas have the best survival, whereas those with small cell carcinomas of the bladder have the worst.
The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate 025 trial.
In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.
Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo cytoreductive nephrectomy vs those who do not.
Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma.
In a small phase 2 study of overweight men with recurrent prostate cancer, consuming less than 20 grams of carbohydrates a day resulted in profound weight loss.
Metastasis and death are more likely to occur among patients with relatively high PSA levels at diagnosis of nmCRPC and rising PSA levels during follow-up.
In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.
Among men who had PSA failure following radiation therapy for localized PCa, those with a long PSA doubling time had an increased risk of PCa mortality if they started androgen-deprivation therapy later.
Black men undergoing radical prostatectomy for prostate cancer are more likely to have indications for adjuvant radiotherapy compared with white men.
Statin use is associated with greater overall survival among men with metastatic castration-resistant prostate cancer and improved survival among patients with high-risk prostate cancer.
In a study, a negative confirmatory prostate biopsy in prostate cancer patients on active surveillance predicts a lower risk of progressing to treatment.
In separate studies, apalutamide and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.
Renal and Urology News Articles
- Gadolinium-Based Contrast May Up Acute Kidney Injury Risk in CKD
- Delayed Prostate Cancer Treatment May Up Relapse Risk
- Review: Desmopressin Decreases Nocturia Episodes
- Surgery, Radiation Regimens for High-Grade PCa Offer Similar Outcomes
- Salvage Prostatectomy May Benefit Some Prostate Cancer Patients
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)